Matches in SemOpenAlex for { <https://semopenalex.org/work/W2216364096> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2216364096 endingPage "e0138229" @default.
- W2216364096 startingPage "e0138229" @default.
- W2216364096 abstract "Background The relative efficacy of lapatinib vs. continuing trastuzumab beyond progression (TBP) in HER2-positive metastatic breast cancer (MBC) patients, who progressed on first-line trastuzumab, is still unclear. The objective of this population based cohort study was to compare outcomes of lapatinib vs. TBP in daily practice. Methods All HER2-positive MBC patients who began second-line anti HER2 therapy between 1st January 2010 and 30th August 2013 were selected from Clalit Health Services’ (CHS) electronic database. Available data on patient and disease characteristics and treatments were analyzed. The primary endpoint was overall survival (OS). Outcomes were compared using the Kaplan-Meier (log-rank) method and Cox proportional hazards model. Results 64 patients received second-line lapatinib and 93 TBP. The two treatment groups were similar in age and co-morbidity rates, but differed in proportion of prior adjuvant trastuzumab (lapatinib: 29.7%, TBP: 16.1%, P = 0.043) and rates of prior brain metastases (lapatinib: 32.8%, TBP: 10.8%, P = 0.01). Lapatinib median OS was 13.0 months (95% CI: 9.5–16.5) vs. 31.0 for TBP (95% CI: 20.6–41.4), P<0.001. On multivariate analysis, longer OS was preserved for TBP, after controlling for differences in age, adjuvant trastuzumab, duration of first-line trastuzumab therapy, brain metastases, visceral metastases and hormonal treatment [Hazard Ratio (HR) = 0.63, 95% CI: 0.40–0.99, P = 0.045]. Conclusion In this comparative cohort study, OS of HER2-positive MBC patients treated with TBP was significantly longer than with lapatinib. These results might be especially relevant in settings where ado-trastuzumab-emtansine (TDM-1), the current preferred agent in this setting, is not available yet for patients." @default.
- W2216364096 created "2016-06-24" @default.
- W2216364096 creator A5009836339 @default.
- W2216364096 creator A5055947595 @default.
- W2216364096 creator A5058266202 @default.
- W2216364096 creator A5060867806 @default.
- W2216364096 creator A5070158409 @default.
- W2216364096 date "2015-09-16" @default.
- W2216364096 modified "2023-10-01" @default.
- W2216364096 title "Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study" @default.
- W2216364096 cites W2040689610 @default.
- W2216364096 cites W2110444464 @default.
- W2216364096 cites W2113450161 @default.
- W2216364096 cites W2118385988 @default.
- W2216364096 cites W2129168200 @default.
- W2216364096 cites W2131178461 @default.
- W2216364096 cites W2134031795 @default.
- W2216364096 cites W2137086207 @default.
- W2216364096 cites W2141393790 @default.
- W2216364096 cites W2148479421 @default.
- W2216364096 cites W2157358083 @default.
- W2216364096 cites W2158158704 @default.
- W2216364096 cites W2163750567 @default.
- W2216364096 cites W2168372454 @default.
- W2216364096 cites W2168814163 @default.
- W2216364096 cites W2318605753 @default.
- W2216364096 doi "https://doi.org/10.1371/journal.pone.0138229" @default.
- W2216364096 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4574060" @default.
- W2216364096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26375590" @default.
- W2216364096 hasPublicationYear "2015" @default.
- W2216364096 type Work @default.
- W2216364096 sameAs 2216364096 @default.
- W2216364096 citedByCount "6" @default.
- W2216364096 countsByYear W22163640962018 @default.
- W2216364096 countsByYear W22163640962019 @default.
- W2216364096 countsByYear W22163640962020 @default.
- W2216364096 countsByYear W22163640962023 @default.
- W2216364096 crossrefType "journal-article" @default.
- W2216364096 hasAuthorship W2216364096A5009836339 @default.
- W2216364096 hasAuthorship W2216364096A5055947595 @default.
- W2216364096 hasAuthorship W2216364096A5058266202 @default.
- W2216364096 hasAuthorship W2216364096A5060867806 @default.
- W2216364096 hasAuthorship W2216364096A5070158409 @default.
- W2216364096 hasBestOaLocation W22163640961 @default.
- W2216364096 hasConcept C121608353 @default.
- W2216364096 hasConcept C126322002 @default.
- W2216364096 hasConcept C143998085 @default.
- W2216364096 hasConcept C168563851 @default.
- W2216364096 hasConcept C203092338 @default.
- W2216364096 hasConcept C207103383 @default.
- W2216364096 hasConcept C2775930923 @default.
- W2216364096 hasConcept C2777329042 @default.
- W2216364096 hasConcept C2779786085 @default.
- W2216364096 hasConcept C2908647359 @default.
- W2216364096 hasConcept C44249647 @default.
- W2216364096 hasConcept C50382708 @default.
- W2216364096 hasConcept C530470458 @default.
- W2216364096 hasConcept C71924100 @default.
- W2216364096 hasConcept C72563966 @default.
- W2216364096 hasConcept C99454951 @default.
- W2216364096 hasConceptScore W2216364096C121608353 @default.
- W2216364096 hasConceptScore W2216364096C126322002 @default.
- W2216364096 hasConceptScore W2216364096C143998085 @default.
- W2216364096 hasConceptScore W2216364096C168563851 @default.
- W2216364096 hasConceptScore W2216364096C203092338 @default.
- W2216364096 hasConceptScore W2216364096C207103383 @default.
- W2216364096 hasConceptScore W2216364096C2775930923 @default.
- W2216364096 hasConceptScore W2216364096C2777329042 @default.
- W2216364096 hasConceptScore W2216364096C2779786085 @default.
- W2216364096 hasConceptScore W2216364096C2908647359 @default.
- W2216364096 hasConceptScore W2216364096C44249647 @default.
- W2216364096 hasConceptScore W2216364096C50382708 @default.
- W2216364096 hasConceptScore W2216364096C530470458 @default.
- W2216364096 hasConceptScore W2216364096C71924100 @default.
- W2216364096 hasConceptScore W2216364096C72563966 @default.
- W2216364096 hasConceptScore W2216364096C99454951 @default.
- W2216364096 hasIssue "9" @default.
- W2216364096 hasLocation W22163640961 @default.
- W2216364096 hasLocation W22163640962 @default.
- W2216364096 hasLocation W22163640963 @default.
- W2216364096 hasLocation W22163640964 @default.
- W2216364096 hasOpenAccess W2216364096 @default.
- W2216364096 hasPrimaryLocation W22163640961 @default.
- W2216364096 hasRelatedWork W1991018829 @default.
- W2216364096 hasRelatedWork W2004505325 @default.
- W2216364096 hasRelatedWork W2037508728 @default.
- W2216364096 hasRelatedWork W2169144202 @default.
- W2216364096 hasRelatedWork W2338354381 @default.
- W2216364096 hasRelatedWork W2420830960 @default.
- W2216364096 hasRelatedWork W2944980276 @default.
- W2216364096 hasRelatedWork W3091784252 @default.
- W2216364096 hasRelatedWork W316677534 @default.
- W2216364096 hasRelatedWork W3177344046 @default.
- W2216364096 hasVolume "10" @default.
- W2216364096 isParatext "false" @default.
- W2216364096 isRetracted "false" @default.
- W2216364096 magId "2216364096" @default.
- W2216364096 workType "article" @default.